Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 13INDUSTRY 7NETWORK 3NIH 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Colorectal Neoplasms 3Colonic Neoplasms 3Urinary Bladder Neoplasms 2Rectal Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 17Magnetic Resonance Spectroscopy 15Gemcitabine 13Cisplatin 8Biopsy 8Radiotherapy 7Mitomycin 6Cystoscopy 6pembrolizumab 5Trastuzumab 5Paclitaxel 5Fluorouracil 5cabozantinib 4atezolizumab 4Radiation 4erdafitinib 3dehydroftorafur 3Transurethral Resection of Bladder 3Sunitinib 3Sorafenib 3Platinum 3Nivolumab 3Mitozytrex 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3valrubicin 2tipifarnib 2sapanisertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Urinary Bladder Neoplasms × BCG Vaccine × Clear all
NCT00002490 2013-12-18

Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Genitourinary

Urinary Bladder Neoplasms

NCT00003759 2013-01-31

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡